Related Articles
Mutational diversity of NS5A and NS3 during triple therapy (telaprevir, pegylated-interferon-α 2b and ribavirin) for genotype 1b chronic hepatitis C: The Kobe Hepatitis Therapeutic Group
Mutations in different regions of the genome of hepatitis C virus genotype 1b and association with response to interferon therapy
MHC class I-related chain B gene polymorphism is associated with virological response to pegylated interferon plus ribavirin therapy in patients with chronic hepatitis C infection
Prediction of a sustained viral response in chronic hepatitis C patients who undergo induction therapy with double filtration plasmapheresis plus interferon-β/ribavirin
Mutations in the STAT1‑interacting domain of the hepatitis C virus core protein modulate the response to antiviral therapy